Market Place
Sourcing Support
MAIA Bio Board Members Engage In Private Placement Financings
24 Dec 2025 //
GLOBENEWSWIRE
MAIA Biotechnology Announces $1.51 Million Private Placement
16 Dec 2025 //
GLOBENEWSWIRE
MAIA`s Ateganosine Advances With Pivotal Phase 3 Trial Launch
11 Dec 2025 //
GLOBENEWSWIRE
MAIA Leaders Back 2025 on Breakthrough Trial Data
11 Dec 2025 //
GLOBENEWSWIRE
MAIA Bio Initiates THIO-104 Ph 3 Trial For Ateganosine
11 Dec 2025 //
GLOBENEWSWIRE
MAIA Targets $50B Immuno Market with Telomere Therapy
10 Dec 2025 //
GLOBENEWSWIRE
MAIA Bio CEO, Directors Buy Shares on Open Market
01 Dec 2025 //
GLOBENEWSWIRE
MAIA Bio Spotlights Ateganosine Program Progress At SITC 2025
21 Nov 2025 //
GLOBENEWSWIRE
MAIA Biotech CEO Highlights Telomere Efficacy in Romania
20 Nov 2025 //
GLOBENEWSWIRE
MAIA Biotech Presents Trial in Progress Poster at Conference
27 Oct 2025 //
GLOBENEWSWIRE
MAIA Bio Reveals 30-Month Survival In Ph 2 Trial in NSCLC Cancer
23 Oct 2025 //
GLOBENEWSWIRE
MAIA Biotechnology Announces $736,600 Private Placement
13 Oct 2025 //
GLOBENEWSWIRE
MAIA Bio To Launch Digital Asset Treasury Strategy For Leading
07 Oct 2025 //
GLOBENEWSWIRE
MAIA Biotechnology Announces $2.25 Million Private Placement
29 Sep 2025 //
GLOBENEWSWIRE
MAIA Bio Gets $2.3M NIH Grant For Thio-101 Cancer Trial
24 Sep 2025 //
GLOBENEWSWIRE
MAIA Bio Reveals Positive THIO-101 Phase 2 Data in Lung Cancer
11 Sep 2025 //
GLOBENEWSWIRE
MAIA Biotech`s Abstract Chosen for Poster at IASLC Conference
05 Sep 2025 //
GLOBENEWSWIRE
Maia Biotechnology Publishes Interim Data on Telomere-Targeting
27 Aug 2025 //
GLOBENEWSWIRE
MAIA Bio Granted EU Patent for Telomere-Targeting Cancer Agents
13 Aug 2025 //
GLOBENEWSWIRE
FDA Fast Tracks MAIA Bio`s Ateganosine for Lung Cancer
28 Jul 2025 //
BUSINESSWIRE
MAIA Bio Publishes Data on Second-Gen Anticancer Drug
17 Jul 2025 //
BUSINESSWIRE
MAIA Begins Ph2 Trial Expansion for Ateganosine in Lung Cancer
09 Jul 2025 //
BUSINESSWIRE
MAIA to Present Posters on Telomere-Targeting Cancer Agents
01 Jul 2025 //
BUSINESSWIRE
MAIA Biotechnology, Roche Partner on Cancer Therapies
26 Jun 2025 //
CONTRACTPHARMA
MAIA Bio Adds Liver Cancer Experts to Scientific Advisory Board
24 Jun 2025 //
BUSINESSWIRE
MAIA Biotech and Roche Sign Clinical Supply Agreement for Cancer
18 Jun 2025 //
BUSINESSWIRE
MAIA Biotechnology to Present at BIO International Convention
10 Jun 2025 //
BUSINESSWIRE
Maia Biotech reports positive Phase 2 THIO-101 trial update
05 Jun 2025 //
BUSINESSWIRE
MAIA Biotechnology Announces New Responder in Lung Cancer Trial
05 Jun 2025 //
BUSINESSWIRE
MAIA Biotechnology Announces $695,000 Private Placement
27 May 2025 //
BUSINESSWIRE
MAIA Biotechnology to Present Poster at ASCO 2025 Annual Meeting
15 May 2025 //
BUSINESSWIRE
MAIA Biotechnology Director Joins Private Placement
14 May 2025 //
BUSINESSWIRE
MAIA Biotechnology Announces $1.08M Private Placement
05 May 2025 //
BUSINESSWIRE
MAIA Biotech CEO Outlines Cancer Immunotherapy Milestones in 2025
01 Apr 2025 //
BUSINESSWIRE
MAIA Biotechnology Poster at ESMO`s European Lung Cancer Congress
25 Mar 2025 //
BUSINESSWIRE
MAIA Biotechnology Publishes Study on THIO Prodrug Potency
20 Mar 2025 //
BUSINESSWIRE
MAIA Bio gets USAN Approval for "Ateganosine" as Anticancer Agent
19 Mar 2025 //
BUSINESSWIRE
MAIA Biotech To Start Ph 3 THIO Trial In Advanced NSCLC
27 Feb 2025 //
BUSINESSWIRE
MAIA Biotech Expands THIO-101 Ph 2 Trial In Advanced NSCLC
26 Feb 2025 //
BUSINESSWIRE
MAIA Biotech Announces $1.43M Non-Brokered Private Placement
24 Feb 2025 //
BUSINESSWIRE
MAIA Biotechnology Announces Private Placement of $2,715,000
18 Feb 2025 //
BUSINESSWIRE
MAIA Biotech Announces Positive Data for THIO-101 in Lung Cancer
04 Feb 2025 //
BUSINESSWIRE
MAIA Biotech, BeiGene Partner For Phase 2 Trials In 3 Cancer Types
07 Jan 2025 //
BUSINESSWIRE
MAIA Biotechnology Announces Director in Recent Placements
19 Dec 2024 //
BUSINESSWIRE
MAIA Biotech Gets FDA Rare Pediatric Disease Designation for THIO
16 Dec 2024 //
BUSINESSWIRE
MAIA Expands Regeneron Supply Deal for NSCLC Phase 2 Trial
03 Dec 2024 //
BUSINESSWIRE
MAIA Biotech Announces Director`s Participation in Private Placement
07 Nov 2024 //
BUSINESSWIRE
MAIA Biotechnology Presents THIO-101 Data at SITC 2024
05 Nov 2024 //
BUSINESSWIRE
MAIA Biotechnology Announces $2.44 Million Private Placement
28 Oct 2024 //
BUSINESSWIRE
MAIA Biotechnology Announces Poster Presentation At ENA 2024
15 Oct 2024 //
BUSINESSWIRE
MAIA Announces Positive THIO Phase 2 Survival Updates
10 Sep 2024 //
BUSINESSWIRE
MAIA Biotechnology to Present Phase 2 Data at H.C. Wainwright Conference
04 Sep 2024 //
BUSINESSWIRE
MAIA Biotechnology Updates Phase 2 Trial Of Cancer Treatment Agent
23 Jul 2024 //
BUSINESSWIRE
MAIA Highlights 2024 Achievements, Anticancer Progress
07 Jun 2024 //
BUSINESSWIRE
FDA Telomerase Approval Shows Viability Of MAIA`s Telomere Approach
07 Jun 2024 //
BUSINESSWIRE
MAIA Highlights Novel Anticancer Agent Progress In 2024
06 Jun 2024 //
BUSINESSWIRE
MAIA Bio: THIO Efficacy In Non-Small Cell Lung Cancer
04 Jun 2024 //
BUSINESSWIRE
MAIA Biotechnology to Present at the BIO International Convention 2024
17 May 2024 //
BUSINESSWIRE
MAIA Biotech Abstract Accepted For ASCO 2024 Poster
16 May 2024 //
BUSINESSWIRE
MAIA Announces Director`s Share Purchase In Private Placement
30 Apr 2024 //
BUSINESSWIRE
